Semaglutide Compounding Ingredient
Harbin Jixianglong Biotech is recalling Semaglutide for compounding use due to CGMP deviations regarding process and endotoxin validation.
Stop using this product immediately and contact the manufacturer or your supplier for further instructions regarding return or disposal.
Why it was recalled
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
How to identify it
UPC 20250911
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing…
Where it was sold
Distributed in US.
Official source
Editorial summary by Recall Canary · last updated 2026-06-05 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification